A four-oil intravenous lipid emulsion improves markers of liver function, triglyceride levels and shortens length of hospital stay in adults: a systematic review and meta-analysis

Xin-Tian Xu,Hui Huang,Meng-Xing Tian,Ren-Chong Hu,Zhu Dai,Xin Jin
DOI: https://doi.org/10.1016/j.nutres.2021.05.003
IF: 3.876
2021-08-01
Nutrition Research
Abstract:<p>Clinical trials have reported that a four-oil intravenous lipid emulsion (SMOFlipid) played a positive role in immune function, but showed inconsistent outcomes compared to other lipid emulsions. A systematic review and meta-analysis was conducted to evaluate the effect of SMOFlipid on liver function, triglycerides (TG), inflammatory markers, and clinical outcomes in hospitalized adults after short-term use compared to others. A search of the PubMed, Medline, Embase, China National Knowledge Infrastructure, and Wanfang databases was performed to identify the included randomized controlled trials (RCTs). Trials with adults who were administrated a short-term course of SMOFlipid were included. A meta-analysis on liver function markers, TG, inflammatory markers, and clinical outcomes was conducted. A total of 18 RCTs with 1188 patients were included. Compared to other lipid emulsions, SMOFlipid was associated with a significant reduction in ALT, AST, γ-glutamyltransferase (γ-GT), total bilirubin (TB), TG, C-reactive protein (CRP) and length of hospital stay(LOS). No effect on serum interleukin 6 (IL-6) levels or adverse events were observed. For adult patients, our meta-analysis indicated that SMOFlipid may be beneficial to the liver and prone to prevent hyperlipidemia. The SMOFlipid also shortened LOS.</p>
nutrition & dietetics
What problem does this paper attempt to address?